Virtual biotech accelerator Autobahn Labs is amping up speed with a new Charles River Laboratories partnership in which the former will gain access to CRL’s drug development capabilities, according to a Wednesday release.

Roche has punted a Pompe disease gene therapy from its pipeline after weighing up the competitive landscape. The Swiss drugmaker made the change in a second-quarter update that also featured news of TIGIT trial closures and a commitment not to make “huge cuts” to the organization.

After 14 years on the board of Moderna, the biotech that became a household name after developing an mRNA vaccine for Covid-19, chemical engineer Robert Langer, Sc.D., is retiring from the company’s board.

A study by the National Institutes of Health (NIH) found that artificial intelligence could help accurately diagnose patients—but the large language model still stumbled when it came to clearly explaining its answers.

A clutch of Johnson & Johnson veterans have burst onto the biotech scene, launching Third Arc Bio with $165 million to take multifunctional antibodies into the clinic in solid tumors and autoimmune diseases.

Moderna recently became the latest biopharma to score an approval to prevent respiratory syncytial virus (RSV), but Merck & Co. hopes to be the next in line with new data showing a monoclonal antibody reduced the incidence of RSV-related infections in infants.

Allarity Therapeutics has received notice from the Securities and Exchange Commission that an enforcement action is pending regarding FDA meetings the biotech had surrounding the new drug application for cancer therapy dovitinib.

Having had to give up on its liver disease ambitions due to a lack of funds, Hepion Pharmaceuticals has decided that its best option is to merge into Israeli biotech Pharma Two B.

Innovent has pulled off another late-phase win for its Eli Lilly-partnered GLP-1 drug candidate, linking the dual agonist to improved outcomes in type 2 diabetes to tee up a filing for approval in China.

As Intuitive Surgical continues to roll out its latest da Vinci robot, following its launch in March, the company warned that supplies may be tight for the next 12 months.